Xi, Liqiang External Entity


Sort by

Selected publications

  • The Genetic Basis of Hepatosplenic T-cell Lymphoma.  Cancer discovery. 2017 In Process GET IT
    Times cited: 1
  • A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.  Clinical cancer research : an official journal of the American Association for Cancer Research2016 Academic Article GET IT
    Times cited: 4